Augmentation of Maxillary Horizontal And Vertical Bone Deficiency Using Mineralized Plasmatic Matrix

Alveolar Ridge Abnormality of Maxilla Clinical Trial

Official title:

Augmentation of Maxillary Horizontal And Vertical Bone Deficiency Using Mineralized Plasmatic Matrix

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03757195
• Other study ID #: CEBC-CU-2017-11-16
• Status: Recruiting
• Phase: N/A
• Start date: November 15, 2018
• Est. completion date: October 25, 2020

Study information

• Verified date: November 2018
• Source: Cairo University
• Contact: Hany M Ahmed, B.D.S
• Phone: 00201091971228
• Email: hanyyusf4[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A new technique of grafting introduce called Mineralized plasmatic matrix. This technique can be used in grafting in anterior zone giving a good results and bone substitution occur using allograft or xenograft.

The bone graft have a good consistency when it mixed with plasma give easy application, strength and stability of the graft. Also plasma rich with CGF (Cellular growth factors).

Description:

Patients suffering from anterior maxillary vertical and horizontal bone loss will be treated using a xeno-graft mixed with the same patient plasma that extracted from his own blood during the operation this graft will be stabilized by collagen membrane and surgical tags.

Patients will be follow up for 6 months to measure amount of bone loss of the xeno-graft during this period post operative using C.B.C.T

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: October 25, 2020
• Est. primary completion date: July 29, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

• Age: from 20 to 40 years old

• no history of previous grafting.

• no History of previous implant placement

• Medically Free e.g no debilitating diseases

Exclusion Criteria:

• Smoker patients.

• Alcoholic patients

• Pregnant.

• Drug Abusers.

• Hypertensive , Diabetic, having Problems or disease in Kidney and/or liver.

• Thyroid Disease.

• Problem in Vit.D absorption or in calcitonin hormone secretion.

• History of blood transfusion or donating blood less than 4 months.

• Patient under Corticosteroid therapy.

• Neurologicaly unstable patients.

• History of radiotherapy or chemo-therapy.

• Patient undergo Spect C.T Scan less than 4 Months .

Related Conditions & MeSH terms

• Alveolar Ridge Abnormality of Maxilla

Intervention

Procedure:
• Augmentation
combination product

Locations

Country	Name	City	State
Egypt	Cairo Univerisity	Cairo
Egypt	Cairo University	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	amount of bone loss	amount of bone loss after xenograft by CBCT	change from baseline at 6 months